20097702

Source:http://linkedlifedata.com/resource/pubmed/id/20097702

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0036043, umls-concept:C0916168, umls-concept:C1274040, umls-concept:C2713495
pubmed:issue	4
pubmed:dateCreated	2010-2-15
pubmed:abstractText	Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-10807749, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-11268266, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-11994249, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-15064100, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-15337694, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-15842977, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-16461038, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-16461040, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-17387129, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-17387131, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-17630038, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-17699012, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-17984165, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-18536749, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-18560005, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-19576325, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-19958854, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-20097704, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-2215607, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-7074948, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-8071609, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-8831911, http://linkedlifedata.com/resource/pubmed/commentcorrection/20097702-9012644
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8006263
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL, http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol Ester Transfer Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Sulfhydryl Compounds, http://linkedlifedata.com/resource/pubmed/chemical/dalcetrapib
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1522-9645
pubmed:author	pubmed-author:BurgessTracyT, pubmed-author:KallendDavidD, pubmed-author:RhyneJames MJM, pubmed-author:RobinsonJennifer GJG, pubmed-author:RothEli MEM, pubmed-author:SteinEvan AEA
pubmed:issnType	Electronic
pubmed:volume	31
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	480-8
pubmed:meshHeading	pubmed-meshheading:20097702-Adolescent, pubmed-meshheading:20097702-Adult, pubmed-meshheading:20097702-Aged, pubmed-meshheading:20097702-Anticholesteremic Agents, pubmed-meshheading:20097702-Cholesterol, HDL, pubmed-meshheading:20097702-Cholesterol Ester Transfer Proteins, pubmed-meshheading:20097702-Coronary Disease, pubmed-meshheading:20097702-Double-Blind Method, pubmed-meshheading:20097702-Drug Administration Schedule, pubmed-meshheading:20097702-Female, pubmed-meshheading:20097702-Humans, pubmed-meshheading:20097702-Lymphatic Diseases, pubmed-meshheading:20097702-Male, pubmed-meshheading:20097702-Mesentery, pubmed-meshheading:20097702-Middle Aged, pubmed-meshheading:20097702-Sulfhydryl Compounds, pubmed-meshheading:20097702-Treatment Outcome, pubmed-meshheading:20097702-Young Adult
pubmed:year	2010
pubmed:articleTitle	Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
pubmed:affiliation	Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA. esteinmrl@aol.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II